Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Urogen Pharma Ltd URGN

Healthcare Biotechnology
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel... see more

Recent & Breaking News (NDAQ:URGN)

UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology

Business Wire November 13, 2023

UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023

Business Wire November 7, 2023

Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024

Business Wire October 3, 2023

Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors

GlobeNewswire September 11, 2023

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 8, 2023

UroGen Pharma to Present at Upcoming Investor Conferences

Business Wire August 31, 2023

UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments

Business Wire August 10, 2023

The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Business Wire August 8, 2023

UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Business Wire August 2, 2023

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 31, 2023

UroGen Announces $120 Million Private Placement of Ordinary Shares

Business Wire July 27, 2023

UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials

Business Wire July 27, 2023

UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors

Business Wire July 25, 2023

Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation

Business Wire July 10, 2023

UroGen Pharma to Host UGN-102 Data Event on July 27, 2023

Business Wire July 6, 2023

Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration

Business Wire June 20, 2023

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 9, 2023

UroGen Pharma to Present at Upcoming Investor Conferences

Business Wire June 2, 2023

UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments

Business Wire May 11, 2023

UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023

Business Wire May 4, 2023